The International Society on Thrombosis and Haemostasis (ISTH) brought thousands of experts from around the world to Melbourne, Australia, this month to hear about the latest research and discuss diagnostic and therapeutic advances.
Immediately following the Congress, CSL Behring hosted more than 60 attendees representing 14 countries on a tour of its leading-edge manufacturing facility in Broadmeadows.
CSL Behring, a global biotechnology leader, develops medicines for people who have rare and serious diseases. It’s a part of CSL Limited – which got its start in Australia more than 100 years ago.
On the Broadmeadows tour, attendees learned about the company’s manufacturing process, as well as its promise to discover, develop and deliver medicines. A key part of CSL Behring’s end-to-end operations, the Broadmeadows facility is currently being expanded to meet increasing demand.
ISTH is the leading worldwide not-for-profit organization dedicated to advancing the understanding, prevention, diagnosis and treatment of thrombotic and bleeding disorders. Its initiatives include education and standardization programs, research activities, peer-reviewed publications, expert committees and yearly congresses.